Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial. J of Skin [Internet]. 2022 Nov. 16 [cited 2025 Oct. 6];6(6):s62. Available from: https://skin.dermsquared.com/skin/article/view/1817